ONESOURCE
Onesource Specialty Pharma Limited
Specialty pharma CDMO focused on semaglutide and injectables manufacturing
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
onesourcecdmo.com(opens the company website in a new tab)Key metrics
Price as of 2026-10-16
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What you need to know
OneSource (Onesource Specialty Pharma) is a contract manufacturing partner to drug companies, making drug-device combination products (cartridges and pens, chiefly for generic semaglutide), sterile injectables, soft gelatin capsules and biologics.
Company snapshot
32ndBy market cap
Ranked among 119 companies in Pharmaceuticals.
What we see
- ✓Debt-to-equity of 0.22x — the company is largely funded by its own money, not borrowed funds.
- ✗Net margin is negative — the company is spending more than it earns right now.
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 68 Cr | 393 Cr | 426 Cr | 327 Cr | 376 Cr | 290 Cr | 428 Cr | 449 Cr |
| Operating expenses (approx.) | 68 Cr | 249 Cr | 243 Cr | 239 Cr | 269 Cr | 273 Cr | 336 Cr | 326 Cr |
| EBITDA | 0.12 Cr | 143 Cr | 183 Cr | 88 Cr | 106 Cr | 17 Cr | 92 Cr | 123 Cr |
| OPM % | 0.2% | 36.5% | 42.8% | 27.0% | 28.3% | 6.0% | 21.5% | 27.5% |
| Other income | 0.58 Cr | 5 Cr | 3 Cr | 5 Cr | 3 Cr | 5 Cr | 2 Cr | 4 Cr |
| Interest | 21 Cr | 46 Cr | 33 Cr | 27 Cr | 34 Cr | 38 Cr | 23 Cr | 31 Cr |
| Depreciation | 19 Cr | 69 Cr | 68 Cr | 68 Cr | 70 Cr | 70 Cr | 72 Cr | 72 Cr |
| Profit before tax | -39 Cr | -67 Cr | 83 Cr | -4 Cr | 6 Cr | -93 Cr | -0.29 Cr | 20 Cr |
| Tax % | 0.0% | -3.5% | -18.6% | 95.8% | -82.6% | 4.6% | 1674.3% | -23.2% |
| Net profit | -39 Cr | -69 Cr | 98 Cr | -0.19 Cr | 10 Cr | -89 Cr | 5 Cr | 25 Cr |
| EPS (₹) | ₹-9.41 | ₹-6.31 | ₹8.61 | ₹-0.02 | ₹0.92 | ₹-7.74 | ₹0.40 | ₹2.18 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
| Sales | 1,445 Cr | 1,422 Cr | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 978 Cr | 1,117 Cr | Sign in free for the trailing twelve months |
| EBITDA | 467 Cr | 304 Cr | Sign in free for the trailing twelve months |
| OPM % | 32.3% | 21.4% | Sign in free for the trailing twelve months |
| Other income | 17 Cr | 15 Cr | Sign in free for the trailing twelve months |
| Interest | 166 Cr | 122 Cr | Sign in free for the trailing twelve months |
| Depreciation | 274 Cr | 279 Cr | Sign in free for the trailing twelve months |
| Profit before tax | -68 Cr | -92 Cr | Sign in free for the trailing twelve months |
| Tax % | 73.5% | 19.7% | Sign in free for the trailing twelve months |
| Net profit | -18 Cr | -74 Cr | Sign in free for the trailing twelve months |
| EPS (₹) | ₹-1.63 | ₹-6.44 | Sign in free for the trailing twelve months |
| Dividend payout % | — | — | Sign in free for the trailing twelve months |
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Equity capital | 11 Cr | 11 Cr |
| Reserves | 5,869 Cr | 5,820 Cr |
| Borrowings | 772 Cr | 1,276 Cr |
| Other liabilities | 898 Cr | 1,102 Cr |
| Total liabilities | 7,550 Cr | 8,210 Cr |
| Fixed assets (net) | 897 Cr | 926 Cr |
| CWIP | 60 Cr | 314 Cr |
| Investments | 16 Cr | 16 Cr |
| Inventories | 158 Cr | 439 Cr |
| Trade receivables | 417 Cr | 690 Cr |
| Cash & bank | 156 Cr | 36 Cr |
| Other assets | 5,846 Cr | 5,790 Cr |
| Total assets | 7,550 Cr | 8,210 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Cash from operating activity | -22 Cr | 9 Cr |
| Cash from investing | -201 Cr | -495 Cr |
| Cash from financing | 1,987 Cr | 359 Cr |
| Net cash flow | 1,765 Cr | -127 Cr |
| Free cash flow (OCF − Capex) | -22 Cr | -561 Cr |
Ratios
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| ROCE % | 1.5% | 0.4% |
| ROE % | -0.3% | -1.3% |
| Debtor days | 105 | 177 |
| Inventory days | 175 | 366 |
| Days payable | 195 | 312 |
| Cash conversion cycle | 86 | 230 |
| OCF / EBITDA % | -4.6% | 2.8% |
| Debt / equity | 0.13 | 0.22 |
| Current ratio | 0.98 | 0.99 |
| Net debt / EBITDA | 1.32 | 4.08 |